Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

James Fung

Showing results (41-50 of 199) with videos related to

Pageof 20
Sort By:
Expert Review of Gastroenterology & Hepatology|March 27, 2023
Chronic hepatitis B: a scoping review on the guidelines for stopping nucleos(t)ide analogue therapyRex Wan-Hin Hui, Lung-Yi Mak, Wai-Kay Seto, et al.
Hepatology International|June 10, 2025
Emerging therapies for HBsAg seroclearance: spotlight on novel combination strategiesRex Wan-Hin Hui, James Fung, Wai-Kay Seto, et al.
Clinical and Molecular Hepatology|January 19, 2023
The role of different viral biomarkers on the management of chronic hepatitis BLung-Yi Mak, Rex Wan-Hin Hui, James Fung, et al.
Hepatology International|February 17, 2025
Expanding treatment indications in chronic hepatitis B: Should we treat all patients?Rex Wan-Hin Hui, Lung-Yi Mak, James Fung, et al.
Expert Opinion on Investigational Drugs|October 30, 2023
Bepirovirsen (GSK3228836) in chronic hepatitis B infection: an evaluation of phase II progressLung-Yi Mak, Rex Wan-Hin Hui, James Fung, et al.
The American Journal of Gastroenterology|April 22, 2008
Prevalence of fibrosis and cirrhosis in chronic hepatitis B: implications for treatment and managementJames Fung, Ching-Lung Lai, David But, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|May 21, 2014
Hepatitis B surface antigen levels after hepatitis B e-antigen seroclearance: a longitudinal follow-up studyJames Fung, Wai-Kay Seto, Danny Ka-ho Wong, et al.
Antiviral Therapy|February 17, 2007
One-year entecavir or lamivudine therapy results in reduction of hepatitis B virus intrahepatic covalently closed circular DNA levelsDanny Ka-Ho Wong, Man-Fung Yuen, Vincent Wing-Shun Ngai, et al.
Journal of Clinical Microbiology|October 19, 2007
Hepatitis B virus core-related antigens as markers for monitoring chronic hepatitis B infectionDanny Ka-Ho Wong, Yasuhito Tanaka, Ching-Lung Lai, et al.
The American Journal of Gastroenterology|December 16, 2010
Mild-to-moderate elevation of alanine aminotransferase increases liver stiffness measurement by transient elastography in patients with chronic hepatitis BJames Fung, Ching-Lung Lai, Charles Cheng, et al.
Pageof 20

Showing results (41-50 of 199) with videos related to

Sort By:
Pageof 20
Expert Review of Gastroenterology & Hepatology|March 27, 2023
Chronic hepatitis B: a scoping review on the guidelines for stopping nucleos(t)ide analogue therapyRex Wan-Hin Hui, Lung-Yi Mak, Wai-Kay Seto, et al.
Hepatology International|June 10, 2025
Emerging therapies for HBsAg seroclearance: spotlight on novel combination strategiesRex Wan-Hin Hui, James Fung, Wai-Kay Seto, et al.
Clinical and Molecular Hepatology|January 19, 2023
The role of different viral biomarkers on the management of chronic hepatitis BLung-Yi Mak, Rex Wan-Hin Hui, James Fung, et al.
Hepatology International|February 17, 2025
Expanding treatment indications in chronic hepatitis B: Should we treat all patients?Rex Wan-Hin Hui, Lung-Yi Mak, James Fung, et al.
Expert Opinion on Investigational Drugs|October 30, 2023
Bepirovirsen (GSK3228836) in chronic hepatitis B infection: an evaluation of phase II progressLung-Yi Mak, Rex Wan-Hin Hui, James Fung, et al.
The American Journal of Gastroenterology|April 22, 2008
Prevalence of fibrosis and cirrhosis in chronic hepatitis B: implications for treatment and managementJames Fung, Ching-Lung Lai, David But, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|May 21, 2014
Hepatitis B surface antigen levels after hepatitis B e-antigen seroclearance: a longitudinal follow-up studyJames Fung, Wai-Kay Seto, Danny Ka-ho Wong, et al.
Antiviral Therapy|February 17, 2007
One-year entecavir or lamivudine therapy results in reduction of hepatitis B virus intrahepatic covalently closed circular DNA levelsDanny Ka-Ho Wong, Man-Fung Yuen, Vincent Wing-Shun Ngai, et al.
Journal of Clinical Microbiology|October 19, 2007
Hepatitis B virus core-related antigens as markers for monitoring chronic hepatitis B infectionDanny Ka-Ho Wong, Yasuhito Tanaka, Ching-Lung Lai, et al.
The American Journal of Gastroenterology|December 16, 2010
Mild-to-moderate elevation of alanine aminotransferase increases liver stiffness measurement by transient elastography in patients with chronic hepatitis BJames Fung, Ching-Lung Lai, Charles Cheng, et al.
Pageof 20